Cambridge Cognition gets $200K grant for Alzheimer’s test
Summary
Cambridge Cognition Ltd, which is developing a clinical diagnostic product that provides early warning of neurodegenerative conditions, has been awarded a grant of $200,000 by the Alzheimer’s Drug Discovery Foundation (ADDF) for the development of a clinical cognitive assessment product for Alzheimer’s disease. ADDF made this award as part of its effort to advance early detection and the reliable assessment of cognitive function in patients with Alzheimer’s disease and related dementias. The company’s Paired Associate Learning (PAL) test is widely regarded as the most accurate current test for the detection of early stage dementia and mild cognitive impairment, as well as accurately differentiating between demented and normal patients and those suffering from depression. “The device and tests being developed by Cambridge Cognition will enable clinicians to accurately identify patients with early dementia. Ian Harris, CEO of Cambridge Cognition, said, “This will really speed up our time to market and is an enormous vote of confidence in both our science and our business model by a highly respected independent charity.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
